MELVILLE, N.Y., Sept. 12 /PRNewswire/ -- Fougera, a division of Nycomed US Inc., today announced the FDA has approved its Clotrimazole Cream USP 1%. The generic formulation compares to Taro's Referenced Listed Drug (RLD) and is available in three sizes: 15g tubes (NDC # 0168-0133-15), 30g tubes (NDC # 0168-0133-30) and 45g tubes (NDC # 0168-0133-46).
"The approval of Clotrimazole Cream is another illustration of Fougera's robust product pipeline," stated David Klaum, Senior Vice President and General Manager Fougera. "With each product approval, Fougera reaffirms its commitment to providing safe, effective and affordable options to health care providers and their patients."
Founded in 1849, Fougera is a division of Nycomed US Inc. and is the leading manufacturer and distributor of a wide range of topical products. For more information on Fougera's complete line of products, please call Fougera Customer Service at (800) 645-9833 or visit the company online at www.fougera.com.
About Nycomed US Inc.
Nycomed US Inc. is a subsidiary of Nycomed. In addition to Fougera, Nycomed US Inc. operates two additional divisions of specialty pharmaceuticals. The PharmaDerm(R) division is dedicated to bringing innovative products to dermatologists so they can best care for their patients. Nycomed US Inc. also markets and sells Savage Laboratories products, which focus on emergency care. More information is available at www.nycomedus.com.
Photo Editor: Image available.
CONTACT: Angie Malone of HLD Public Relations, +1-516-536-2020,
email@example.com, for Fougera
Web site: http://www.fougera.com/